462 results about "Intestinal inflammation" patented technology

The invention discloses an enteritis patient condition severity risk early warning method, a medium and equipment. The method comprises the following steps: acquiring a borborygmus original signal and a clinical multi-dimensional physiological parameter sequence through a sensing device; constructing a borborygmus dynamic characteristic spectrum based on the borborygmus original signal to generate an acoustic biomarker time sequence; inputting the acoustic biomarker time sequence and the clinical multi-dimensional physiological parameter sequence into a multi-modal fusion early warning model to obtain an intestinal inflammation risk index; executing a signal quality self-evaluation process and generating a data quality warning code when the signal quality is abnormal; triggering a multi-node collaborative monitoring mechanism based on the risk index to generate an intestinal state multi-dimensional situation map; establishing an individualized risk baseline and generating a graded early warning instruction; and finally outputting a comprehensive early warning report. According to the method, multi-modal fusion analysis of the borborygmus signal and the clinical parameters is realized, the accuracy and timeliness of illness state early warning are remarkably improved through dynamic risk assessment and signal quality monitoring, and a reliable basis is provided for clinical decision making.

The invention provides infant formula milk powder for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the infant formula milk powder. The invention provides infant formula milk powder for the first time, the infant formula milk powder comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The infant formula milk powder can improve intestinal inflammation and / or microbial disorder.

The invention provides lactobacillus reuteri HNU872 and application of the lactobacillus reuteri HNU872 in preparation of intestinal inflammation related products. The invention discloses how the Lactobacillus reuteri HNU872 effectively alleviates the phenotype of DSS-induced mouse enteritis. The invention also discloses a preparation method of the Lactobacillus reuteri HNU872. Research results show that the Lactobacillus reuteri HNU872 can significantly relieve weight loss caused by enteritis, improve colon length, significantly improve the level of anti-inflammatory cytokines in serum and reduce the concentration of pro-inflammatory cytokines. In addition, the expression of the intestinal tight junction protein ZO-1 is obviously promoted. The lactobacillus reuteri HNU872 can regulate diversity and structure of intestinal microbiota of mice, inhibit enrichment of pathogenic bacteria and relieve inflammatory response. According to the invention, the action mechanism of the lactobacillus reuteri HNU872 in improving enteritis is clarified, and a solid scientific basis is provided for developing a microbial product based on probiotics as an alternative treatment strategy for ulcerative colitis.

The invention relates to the technical field of functional microorganism screening and application, and particularly provides a strain of lactobacillus plantarum and an application of the lactobacillus plantarum in improvement of intestinal inflammation and repair of intestinal mucosa injury. The plant lactobacillus is preserved in the China General Microbiological Culture Collection Center (CGMCC for short) on August 1, 2024, the address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the plant lactobacillus is CGMCC No.31521. The strain has remarkable antioxidant, bacteriostatic and anti-inflammatory effects, can repair intestinal barrier injury of mice with colitis, promote renewal of intestinal stem cells, promote growth of intestinal beneficial bacteria and inhibit proliferation of harmful bacteria, can be widely applied to prevention and treatment of enteritis, and has a wide market prospect.

To provide beta-1,3-glucan, and to provide uses thereof for regulating immunity in the human body, which are methods for treating and / or preventing high cholesterol, diabetes, and allergies, and methods for treating and / or preventing intestinal inflammation.SOLUTION: Provided is a composition for oral administration for alleviating symptoms associated with intestinal inflammation in humans, the composition containing an effective amount of beta-1,3-glucan dried to a moisture content of about 40% or less from Euglena grown by fermentation, the beta-1,3-glucan not containing beta-1,6-glycosidic bonds, the effective amount being between 0.1 mg of beta-1,3-glucan / kg body weight and 100 mg of beta-1,3-glucan / kg body weight.SELECTED DRAWING: Figure 1

The invention discloses a polymer drug-loaded particle for targeted adhesion to an intestinal inflammation area and a preparation method and application thereof.The method includes the steps that degradable polymer drug-loaded particles are subjected to surface modification through polycations and then added into a monomer solution of an adhesion layer, particle surface in-situ polymerization is initiated through ultraviolet irradiation, and a PAN adhesion layer is formed; the adhesion layer modified polymer drug-loaded particles are obtained. Wherein the polycation is used as a middle layer, so that the PAN adhesion layer can be successfully modified. Carboxyl in the adhesion layer enables the particles to present negative charges, meanwhile, succinimide ester can react with amino naturally existing on the surface of inflammatory intestinal tissue to generate an amide covalent bond, and finally targeted adhesion of the intestinal inflammation part is achieved. According to the adhesion strategy, the PAN can be effectively applied to the micro-nano-scale drug-loaded particles so as to enhance the adhesion of the micro-nano-scale drug-loaded particles in an intestinal tract damaged area, and a brand new thought is provided for treating inflammatory intestinal tracts.

The invention discloses a livestock composite biological feed prepared from probiotics and a method thereof, and relates to the technical field of livestock feeds. The compound biological feed for the livestock and poultry is prepared from the following raw materials: lactobacillus plantarum BNCC138404, bacillus coagulans BNCC132591, bacillus velezensis BNCC352076, bifidobacterium bifidum BNCC186493, aspergillus niger BNCC147472, enterococcus faecalis BNCC186075, yarrowia lipolytica BNCC193899, nutrient substances, mineral trace elements, vitamins, amino acids and prebiotics. The compound biological feed for the livestock and poultry is prepared from the following raw materials: lactobacillus plantarum BNCC138404, bacillus coagulans BNCC132591, bacillus velezensis BNCC352076, bifidobacterium bifidum BNCC186493, aspergillus The compound biological feed fermented by adopting various probiotics can improve the antioxidant level of the broiler chicken, improve the health condition of intestinal tracts, increase the villus height and the villus-implicit ratio of the jejunum of the broiler chicken and reduce the occurrence of intestinal inflammation, so that the growth performance of the broiler chicken is promoted, and the immune performance of the body is improved.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus paracasei strain and application thereof. The invention discloses a Lactobacillus paracasei strain, the name of the Lactobacillus paracasei strain is Lactobacillus paracasei WG-Lpc 63, the Lactobacillus paracasei strain is preserved in China General Microbiological Culture Collection Center on August 27th, 2024, and the preservation number is CGMCC No. 31768. The Lactobacillus paracasei strain is named as Lactobacillus paracasei WG-Lpc 63, and the Lactobacillus paracasei strain is named as Lactobacillus paracasei WG-Lpc 63. The strain disclosed by the invention has good acid production capacity, cholate tolerance and intestinal tract adhesion capacity, and has the effects of regulating intestinal flora balance and relieving intestinal inflammation.

The invention discloses a strain of Lactobacillus paracasei SX-G1520 and an application of the Lactobacillus paracasei SX-G1520 in preparation of a lipid-lowering, anti-inflammatory and / or antioxidant product, the preservation number of the Lactobacillus paracasei SX-G1520 is CCTCC (China Center for Type Culture Collection) No: M 2025032, and the Lactobacillus paracasei SX-G1520 is preserved in the China Center for Type Culture Collection on January 6, 2025. The Lactobacillus paracasei SX-G1520 strain provided by the invention has lipid-lowering and antioxidant functions, significantly reduces the content of intestinal neutrophils of a zebra fish inflammatory bowel disease model, shows a significant effect on relieving intestinal inflammation, is good in safety, and has good application prospects. And a new technical choice is provided for developing probiotic preparations for regulating fat metabolism, resisting oxidative stress and preventing and treating inflammatory bowel diseases.

The invention discloses an inflammatory bowel disease model, a construction method and application thereof and a drug evaluation method based on the inflammatory bowel disease model, and belongs to the technical field of inflammatory bowel disease model construction. A highly bionic intestinal crypt-villus three-dimensional structure is formed based on self-organization of an intestinal cell line C2BBe1, the intestinal crypt-villus three-dimensional structure and a DMEM complete medium containing dextran sulfate sodium are added into an upper chamber of a double-layer culture chamber Transwell, the DMEM complete medium is added into a lower chamber of the double-layer culture chamber Transwell, culture is performed for 2 days, and the inflammatory bowel disease model is obtained. The method takes effect quickly and is highly simulated, the obtained model can simulate the space-time dynamic development process of intestinal inflammation molecular characteristics, and the natural recovery model and the drug treatment model constructed based on the model can provide a brand new platform for researching an inflammation regression mechanism and a drug intervention effect.

The invention discloses an inulin gel compound loaded with Prussian blue nano-enzyme and nattokinase and application of the inulin gel compound in treatment of inflammatory bowel disease, the compound is formed by blending the Prussian blue nano-enzyme, the nattokinase and inulin, the Prussian blue nano-enzyme with multiple antioxidant enzyme activities is used for removing a large amount of active oxygen in cells, and the nattokinase is used for treating inflammatory bowel disease. The level of inflammatory factors is reduced, oxidative stress is relieved, and intestinal inflammation is treated; the nattokinase not only can inhibit the formation of intestinal microthrombus and effectively dissolve thrombus through the excellent thrombolysis capability of the nattokinase, but also can synergistically and effectively treat inflammatory bowel diseases through the intestinal microbiota regulation capability of the nattokinase; in addition, the inulin, the Prussian blue nano-enzyme and the nattokinase jointly realize the regulation of intestinal microbiota of the patient with the inflammatory bowel disease, so that the anxiety and depression symptoms related to the inflammatory bowel disease are effectively relieved through microbiota-intestine-brain axis. In general, the invention provides a creative example for treating the inflammatory bowel disease and related intestinal internal and external complications thereof.

The invention discloses a medicinal and edible homologous compound based on probiotic fermentation synergy and application of the medicinal and edible homologous compound in blood sugar regulation and control, and belongs to the technical field of microorganisms and fermentation engineering. The preparation method comprises the following steps: respectively carrying out two-stage fermentation on aloe, mulberry leaves and liquorice by utilizing saccharomyces cerevisiae BLCC4-0032 and plant lactobacillus DFR-1, so as to obtain a fermentation mixture; the preparation method comprises the following steps: fermenting a fermentation mixture, adding balsam pear peptide into the fermentation mixture to obtain a medicinal and edible compound, forming a metabolic closed loop, and cooperatively regulating a'blood sugar-liver-intestinal flora axis', thereby providing a new solution for diabetes intervention, and opening up a new path for preventing non-alcoholic fatty liver and intestinal inflammation caused by glucose and lipid metabolism disorder.

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The invention belongs to the technical field of biology, and particularly relates to a composition containing plant-derived exosomes as well as a preparation method and application of the composition. The invention provides a composition containing plant-derived exosomes. The composition is prepared from the following components in parts by mass: 1-60 parts of a plant-derived exosome preparation, 1-60 parts of chitosan oligosaccharide and 1-60 parts of probiotics. According to the composition provided by the invention, the plant-derived exosome, the probiotics and the chitosan oligosaccharide are compounded according to a specific proportion, so that the abundance of effective flora can be increased for a long time, the composition of intestinal flora can be improved, the structural balance of the intestinal flora can be regulated and maintained, the intestinal inflammation can be remarkably inhibited, the intestinal leakage can be improved, and the oxidative stress can be resisted; the repair of damaged intestinal mucosa and the elimination of inflammation are facilitated. The composition is safe and stable in raw materials, free of toxic and side effects and capable of being taken as daily diet.

The invention provides a children formula food for improving intestinal inflammation and / or microbial disorder as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or child formula food, the infant formula food comprises 2 '-fucosyllactose and lactose-N-neotetraose, and the mass ratio of the 2'-fucosyllactose to the lactose-N-neotetraose is (1-5.5): 1. The children formula food can improve intestinal inflammation and / or microbial disorder.

The invention relates to a montmorillonite-probiotic microsphere preparation as well as a preparation method and application thereof, the microsphere preparation comprises montmorillonite, a probiotic biofilm and functional small molecules, and microspheres of the microsphere preparation are prepared by crosslinking sodium alginate in a collection solution based on a microfluidic technology. The microsphere preparation is mainly used for oral delivery of montmorillonite-probiotic biofilms and functional small molecules, so as to treat intestinal diseases. Compared with the prior art, the microsphere preparation provided by the invention has the advantages of gastric acid invasion resistance, intestinal responsive release and the like, and can effectively treat intestinal inflammation. In addition, the probiotic biofilm wrapped by the microspheres can enhance the interaction with the intestinal mucosa and prolong the residence time in the intestinal tract. Meanwhile, the used functional small molecules have excellent anti-inflammatory and intestinal barrier repairing effects, and can cooperate with the probiotics to regulate and control intestinal flora, so that the intestinal health is further improved.

The invention relates to the technical field of microorganisms, and provides Witzia ciliaris KY009 (preservation number is CGMCC (China General Microbiological Culture Collection Center) NO. 33480) and Clostridium butyricum KY002 (preservation number is CGMCC NO. 33478), and the two strains are separated from an excrement sample. Experiments prove that the two strains can obviously improve the sperm quality and quantity, regulate the sex hormone level, improve the intestinal inflammation symptom and regulate the expression of related inflammatory factors. The invention also provides a composition containing the two strains, wherein the composition comprises a food composition, a pharmaceutical composition, a health-care product composition, a functional microbial agent and the like. The compositions are useful for improving reproductive health, modulating sex hormone levels, treating intestinal inflammation and promoting mucosal repair, and alleviating metabolic and immune related diseases. The strain and the composition provided by the invention have wide application prospects in the fields of medicines, foods and health-care products.

The invention relates to the technical field of microorganisms, in particular to lactobacillus rhamnosus capable of preventing or treating inflammatory bowel diseases and promoting digestion and application of the lactobacillus rhamnosus, and belongs to the technical field of biological medicine. The invention provides a strain of lactobacillus rhamnosus R7970, wherein the preservation number of the lactobacillus rhamnosus R7970 is CGMCC (China General Microbiological Culture Collection Center) 22244, and the preservation number of the lactobacillus rhamnosus R7970 is CGMCC 22244. The lactobacillus rhamnosus R7970 can be used for effectively preventing inflammatory enteritis (IBD) and has a prevention effect on intestinal inflammation, and meanwhile, the lactobacillus rhamnosus R7970 can be used for improving the nutrition digestion and absorption functions of intestinal tracts. Therefore, the lactobacillus rhamnosus R7970 can be applied to prevention of IBD, can be used for preparing probiotic preparations, common foods, health foods and biological pharmacy for improving intestinal health, is convenient for industrial production, and has great popularization value.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The invention discloses a personalized diet recommendation method for enteritis patients, a medium and equipment. The method comprises the following steps: continuously collecting diet image data, physiological state time sequence data and subjective symptom feedback data; performing food material component deconstruction and cooking mode identification on the diet image through a convolutional neural network, and generating a structured diet vector; analyzing physiological state time sequence data by using a hidden Markov model, and constructing an individualized physiological rhythm map; establishing a symptom triggering condition probability matrix based on a multi-modal association mining algorithm; generating an exploratory diet scheme according to the real-time physiological state of the user and the conditional probability matrix; dynamically updating the conditional probability matrix through an online reinforcement learning mechanism; and finally, periodically outputting a personalized diet taboo list and a safety exploration list. According to the method, through the dynamic correlation analysis of fusing the time sequence physiological features and the dietary components, accurate matching of diet recommendation and individual intestinal tract state fluctuation is realized, and the individuation and adaptability of diet intervention are effectively improved.

The invention discloses a traditional Chinese medicine effective component compound preparation for inhibiting colorectal cancer transformation, which is composed of palmatine, berberine, coptisine and aesculin, and the mass ratio of the palmatine to the berberine to the coptisine to the aesculin is 3: 3: 1: 3. The traditional Chinese medicine active ingredient compound preparation can be prepared into clinical common preparations including granules, capsules or oral liquid according to a conventional method. The traditional Chinese medicine effective component compound preparation disclosed by the invention is proved to be capable of inhibiting intestinal inflammation, improving the intestinal barrier function and remarkably inhibiting colorectal tumor in an inflammatory state by intervening a mouse DSS induced chronic colitis model and an AOM / DSS combined induced colitis and proctitis cancer transformation model.

The invention belongs to the technical field of biological medicines, and particularly relates to application of extracellular vesicle-like particles derived from divaricate saposhnikovia roots in preparation of medicines for preventing and treating intestinal diseases. Research on the physiological efficacy of the extracellular vesicle-like particles from divaricate saposhnikovia root shows that the extracellular vesicle-like particles can relieve colon shortening and colon tissue damage caused by dextran sodium sulfate, relieve intestinal inflammation and promote repair of intestinal barriers including mechanical barriers, chemical barriers and immune barriers. The polypeptide has potential for preparing the medicine for treating the intestinal diseases, and a new strategy is provided for preventing or treating the intestinal diseases.

The invention discloses a fusion antibacterial peptide BMAP18-BSN37 and application thereof, and belongs to the technical field of gene engineering. The nucleotide sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 1, and the amino acid sequence of the fusion antibacterial peptide BMAP18-BSN37 is as shown in SEQ ID NO. 2. The fusion antibacterial peptide BMAP18-BSN37 gene is inserted into a pNZ8148 expression vector to construct a recombinant expression vector pUBB, so that protein aggregation or degradation in cells can be avoided, and the survival rate of strains and the stability of protein expression are improved. The method comprises the following steps: transferring a plasmid pUBB into a lactic acid bacteria NZ9000 strain through electrotransformation, and screening a recombinant lactic acid bacteria strain capable of expressing a fusion protein BMAP18-BSN37 to obtain a recombinant strain NZ-BB; the recombinant lactic acid bacteria NZ-BB strain shows a remarkable prevention effect in an animal infection model, and can effectively reduce bacterial colonization and relieve pathological injury; the Salmonella strain has the potential of being used as an animal feed additive, can reduce the use of antibiotics and chemicals, slow down the development of bacterial drug resistance, improve animal immunity and slow down intestinal inflammation caused by salmonella, and provides support for effectively preventing the health of livestock and poultry.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention discloses an insoluble dietary fiber-EGCG (epigallocatechin gallate) compound as well as a preparation method and application thereof, and belongs to the field of food processing. The preparation method of the insoluble dietary fiber-EGCG compound comprises the following steps: dispersing insoluble dietary fibers in a phosphate buffer solution, fully expanding, uniformly mixing with an EGCG solution dissolved in the phosphate buffer solution, standing at room temperature for a period of time, centrifuging, taking precipitate, and drying to obtain the insoluble dietary fiber-EGCG compound. The insoluble dietary fiber-EGCG compound disclosed by the invention has the advantages that the intestinal inflammation in a mouse colitis model is obviously relieved, and the effect is far better than that of independently using HPSIDF or EGCG; and the HPSIDF-EGCG compound can synergistically regulate and control intestinal flora-immune axis and improve the intestinal barrier function, has mild adsorption reaction conditions, is suitable for industrial production, and is expected to be developed into a product with high additional value.

The invention discloses application of pinoresinol diglucoside in increasing short-chain fatty acids in postmenopausal intestinal tracts and relieving postmenopausal intestinal inflammation, and belongs to the field of medicines. The pinoresinol diglucoside can regulate the abundance of bacteria such as Akecmann bacteria, other mycobacteria, parabacteroides and ruminococcus in intestinal tracts and promote the expression of short-chain fatty acids in the postmenopausal intestinal tracts, so that the postmenopausal intestinal inflammation and osteoporosis are relieved. The invention opens up a new clinical approach for treating diseases related to intestinal flora disorder of postmenopausal women.

The invention relates to a pterostilbene compound, a pharmaceutical composition and application of the pterostilbene compound in preparation of anti-inflammatory drugs. The compound shown in the formula (I) or the pharmaceutically acceptable salt thereof provided by the invention has relatively high stability and high bioavailability, can effectively improve symptoms such as colon shortening, diarrhea, hematochezia and weight loss caused by DSS-induced mouse colitis, has a remarkable inhibition effect on intestinal inflammation, and can be used for preparing anti-inflammatory drugs. # imgabs0 #

The invention relates to a medicine composition for treating inflammatory bowel disease, a medicine combination and application thereof. The pharmaceutical composition is prepared from inulin and fucoidin, the medicine combination comprises a first medicine preparation and a second medicine preparation, the active ingredient of the first medicinal preparation is inulin; the active ingredient of the second medicinal preparation is fucoidin. The pharmaceutical composition disclosed by the invention can effectively balance the level of proinflammatory and anti-inflammatory factors in a body, remarkably reduce and control intestinal inflammation, enhance the barrier function of intestinal tracts and relieve oxidative stress injury of tissues, can be used for preventing and treating inflammatory bowel diseases, is high in safety and is suitable for being taken for a long time. The medicine combination can provide self-selection of medicines, is convenient for patients to take medicines, and improves the dependency of the patients.

The invention belongs to the related technical field of pet prescription food products, and particularly relates to a prescription food for pet dogs with acute intestinal inflammation and a preparation method of the prescription food, the prescription food comprises various components such as rice, barley, chicken powder and corn protein powder, and probiotics are self-made and comprise bifidobacterium, lactobacillus acidophilus and lactobacillus casei. The preparation method comprises the steps of quantitative raw material weighing, auxiliary agent grinding, constant-temperature accurate grinding, adding of specific components for accurate grinding again, heat preservation, deodorization and degassing, drop casting forming, cooling, packaging, sealed storage and the like. Compared with the prior art, the prescription food is high in safety, and feeding tests of healthy dogs have no abnormity; clinical cases show that the leucocyte number and the inflammatory factor content of sick dogs can be reduced; the intestinal barrier can be repaired, so that the intestinal mucosa repair is accelerated; intestinal flora can be improved, and the content of short-chain fatty acid in excrement is increased; the nutrition state can be maintained, and the weight loss range of sick dogs is reduced.

The invention relates to an establishment method and application of in-vitro intestinal inflammation models of mice of different ages, and relates to the technical field of biology. According to the invention, young, adult, middle-aged and old wild type (WT) and TLR4 gene deletion type (TLR4 <- / ->) mice are selected, colon tissues are cultured in vitro, inflammatory response is induced by using interleukin-1beta (IL-1beta) stimulation, an age-related intestinal inflammation model is constructed, the inflammation phenotype of the mouse model and the activity of a TLR4 / MyD88 / NF-kappa B signaling pathway are determined by comparing WT and TLR4 <- / ->, and the age-related intestinal inflammation model is constructed. The core function of the TLR4 in regulating age-dependent intestinal barrier dysfunction is defined, a regulatory network of the TLR4 in intestinal immune aging and flora-host interaction is disclosed, and an age personalized medical strategy is promoted. According to the invention, an efficient and customizable multi-age in-vitro intestinal inflammation model is constructed, and an innovative platform is provided for mechanism analysis and intervention drug screening of TLR4 targeted therapy and age-related intestinal diseases.